Related Experiment Video

Updated: May 26, 2026

Closed-Loop Neurostimulation for Biomarker-Driven, Personalized Treatment of Major Depressive Disorder
05:19

Closed-Loop Neurostimulation for Biomarker-Driven, Personalized Treatment of Major Depressive Disorder

Published on: July 7, 2023

Neuroimaging markers of cellular function in major depressive disorder: implications for therapeutics, personalized

J H Meyer1

  • 1Mood and Anxiety Division and Research Imaging Centre, Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada. jeff.meyer@camhpet.ca

Clinical Pharmacology and Therapeutics
|January 6, 2012
PubMed

Insights

Major depressive episodes (MDE) affect many, with inadequate treatment response. Neuroimaging reveals depression subtypes and elevated monoamine oxidase-A (MAO-A) binding, guiding new treatment development.

Area of Science:

  • Neuroscience
  • Psychiatry
  • Medical Imaging

Background:

  • Major depressive episode (MDE) affects 15% of individuals, with 40% experiencing inadequate treatment response.
  • Neuroimaging offers insights into MDE subtypes, onset mechanisms, and optimizing novel treatments.
  • Understanding neurobiological markers is crucial for advancing depression treatment.

Purpose of the Study:

  • To identify major depressive episode (MDE) subtypes using neuroimaging.
  • To investigate neuroimaging markers associated with MDE onset and progression.
  • To evaluate the target occupancy of novel antidepressant treatments.

Main Methods:

  • Neuroimaging techniques were employed to assess monoamine oxidase-A (MAO-A) binding, glutamate levels, and various receptor/transporter indexes (5-HT(2A), 5-HTT, 5-HT(1A), 5-HT(1B), dopamine D(1) and D(2)).
  • Hippocampal volume was also measured.
  • Clinical trial data on selective serotonin reuptake inhibitor (SSRI) occupancy were analyzed.

Main Results:

  • Specific symptoms like pessimism and motor retardation correlate with distinct depression subtypes.
  • Elevated MAO-A binding in the prefrontal and anterior cingulate cortex is linked to MDE and high-risk states.
  • Selective serotonin reuptake inhibitors (SSRIs) achieved 80% 5-HTT occupancy in clinical trials, despite wide in vitro affinity variations.

Conclusions:

  • Neuroimaging can differentiate MDE subtypes and identify biological markers of disease.
  • Elevated MAO-A binding represents a potential biomarker for MDE and at-risk individuals.
  • Further occupancy studies are essential for accelerating the development of effective depression therapeutics.

More Related Videos

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method07:12

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Published on: August 2, 2021

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

Related Concept Videos

Brain Imaging01:14

Brain Imaging

Brain imaging technologies provide critical insights into both the structure and function of the human brain, enabling medical professionals and researchers to diagnose, study, and treat neurological disorders or psychiatric disorders more effectively.
These technologies include computerized axial tomography (CAT or CT scans), positron-emission tomography (PET scans),  magnetic resonance imaging (MRI),  functional magnetic resonance imaging (fMRI), and Transcranial Magnetic Stimulation (TMS).
Depression: Overview01:18

Depression: Overview

Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
Depressive Disorders: Etiology01:27

Depressive Disorders: Etiology

Depressive disorders result from a complex interplay of biological, psychological, and sociocultural factors, each contributing uniquely to the development and persistence of the condition. Understanding these factors provides critical insight into the multifaceted nature of depression.
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Long-term Depression01:03

Long-term Depression

Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over time, all...